Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Dermatologic 1CNS 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Metastatic Solid Tumors 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 65Nivolumab 56Ipilimumab 34Specimen Handling 23Magnetic Resonance Spectroscopy 21Cyclophosphamide 17Biopsy 13Radiosurgery 12relatlimab 11fludarabine 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 8dabrafenib 8lifileucel 7encorafenib 7aldesleukin 7atezolizumab 6Interleukin-2 6cemiplimab 5X-Rays 5Paclitaxel 5Immunoglobulin G 5Blood Specimen Collection 5Taxes 4Radiotherapy 4Pemetrexed 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × bintrafusp alfa protein, human × 90 days × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡